ACHLAchilles Therapeutics plc

Nasdaq achillestx.com


$ 0.71 $ 0.01 (1.8 %)    

Friday, 13-Sep-2024 10:07:45 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 0.7228
$ 0.71
-- x --
-- x --
$ 0.71 - $ 0.71
$ 0.63 - $ 1.76
18,954
na
28.89M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-achilles-therapeutics-lowers-price-target-to-6

Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target...

 piper-sandler-downgrades-achilles-therapeutics-to-neutral-lowers-price-target-to-2

Piper Sandler analyst Joseph Catanzaro downgrades Achilles Therapeutics (NASDAQ:ACHL) from Overweight to Neutral and lowers ...

 dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...

 why-staar-surgical-shares-are-trading-higher-by-around-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...

 nasdaq-surges-1-conagra-brands-posts-upbeat-earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...

 achilles-therapeutics-q4-eps-046-may-not-be-comparable-to-014-estimate-cash-position-of-1315m-supports-operations-through-2025

Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate ...

 achilles-therapeutics-provides-interim-phase-12a-update-on-clonal-neoantigen-reactive-t-cells-in-advanced-nsclc-and-melanoma-including-first-patients-dosed-with-enhanced-host-conditioning

Improved VELOS manufacturing process delivering higher cNeT doses. Protocols updated to evaluate the benefit of enhanced hos...

 b-of-a-securities-downgrades-achilles-therapeutics-to-underperform-lowers-price-target-to-05

B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers th...

 achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement

Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell ther...

 chardan-capital-reiterates-buy-on-achilles-therapeutics-maintains-11-price-target

Chardan Capital analyst Geulah Livshits reiterates Achilles Therapeutics (NASDAQ:ACHL) with a Buy and maintains $11 price ta...

 achilles-therapeutics-q2-eps-042-inline-cash-position-of-144m-supports-operations-through-2025

Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. Th...

 chardan-capital-maintains-buy-on-achilles-therapeutics-lowers-price-target-to-11

Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION